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Received September 22, 2011; accepted May 9, 2012AbstractPhotodynamic therapy (PDT) has been used in treating peripheral retinal capillary hemangioma (RCH) with satisfactory results. We report a
rare case of von Hippel-Lindau (VHL) disease with three large peripheral RCHs, treated with PDT and intravitreal bevacizumab injection (IVB),
who developed persistent bullous exudative retinal detachment (RD) despite significant tumor regression. The patient is a sporadic case of VHL
disease, with a de novo nonsense mutation in codon 161 with C/ T transition at nucleotide position 694 of the VHL gene. Multiple RCHs were
noted in both eyes. Four small RCHs were found in the left eye and were treated with laser photocoagulation. Three large RCHs in the peripheral
retina of the right eye were complicated with cystoid macular edema and subretinal fluid accumulation. The RCHs were treated with PDT
combined with IVB, and bullous exudative RD developed on the second day after treatment. Three months after PDT, the tumors had regressed
significantly, but exudative RD persisted, despite multiple IVB and intravitreal triamcinolone acetonide injection (IVTA). External drainage with
sclera buckling, IVB, and IVTA were performed, and the retina attached after surgical intervention. The application of PDT in the treatment of
RCHs and its possible complications are discussed.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Retinal capillary hemangioma (RCH) is a benign vascular
tumor which may occur sporadically or as a manifestation of
von Hippel-Lindau (VHL) disease.1 The visual prognosis is
usually unfavorable, due to exudation from the tumor, causing
intraretinal edema or exudative retinal detachment (RD).
According to its location, RCH can be classified as a periph-
eral or a juxtapapillary type. Current treatment modalities for* Corresponding author. Dr. Ling-Ing Lau, Department of Ophthalmology,
Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112,
Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.09.001RCH include laser photocoagulation, cryotherapy, radio-
therapy, traspupillary thermotherapy, and vitreoretinal sur-
gery.1,2 Laser photocoagulation and cryotherapy are the two
major conventional therapies, and are effective as the sole
method of treatment in controlling 74% and 72% of peripheral
tumors, respectively.2 However, larger tumors need multiple
sessions of therapy, which may cause extensive exudative RD.
In recent years, photodynamic therapy (PDT) has been used in
treating large peripheral RCH with satisfactory results.3 Most
tumors regress with decreased exudation. We report a rare case
of VHL disease, with three large peripheral RCHs treated with
PDT and intravitreal bevacizumab injection (IVB), who
developed persistent bullous exudative RD despite significant
tumor regression.hinese Medical Association. All rights reserved.
53F.-Y. Tsai et al. / Journal of the Chinese Medical Association 77 (2014) 52e562. Case report
A 23-year-old Taiwanese female had blurred vision in the
right eye for 5 months. She had a past history of multiple
intramedullary hemangiomas and had received two neuro-
surgeries to excise tumors at 14 years old and 22 years old.
Reviewing the medical history of her family members, there
was no known history of VHL disease or associated tumors.
Genotyping of the VHL gene was performed after obtaining
informed consent from the patient and her family members.
Genomic DNA was extracted from peripheral venous blood
samples. The three exons of the VHL gene were amplified by
polymerase chain reaction (PCR) and sent to the National
Yang-Ming University Genome Research Center for
genotyping.Fig. 1. (A) Three large retinal capillary hemangiomas in the peripheral retina in the
the macula; (B) decreased subretinal fluid and lipid exudate were noted at 1 week af
therapy and intravitreal bevacizumab injection, the tumors showed significant regr
persisted (below arrowheads) despite oral prednisolone and intravitreal injection of b
resolved subretinal fluid at 3 months after surgical intervention.The presenting best-corrected visual acuity (BCVA) was
3/60 in the right eye and 6/5 in the left eye. Therewere no cells or
flare in the anterior segment. Fundus examination revealed three
large peripheral RCHs in the right eye, with prominent feeding
arteries and tortuous dilated draining veins, complicated with
subretinal fluid accumulation (Fig. 1A). Optical coherent
tomography (OCT) showed marked cystoid macular edema and
subretinal fluid accumulation at the macula (Fig. 2A). Fluo-
rescein angiography of the tumors showed early hyper-
fluorescence with profound late leakage (Fig. 3). There were
also four small peripheral RCHs in the left eye (Fig. 4A and B).
The tumors in the left eye were treated with focal photocoagu-
lation and regressed to gliotic nodules (Fig. 4C).
After obtaining informed consent, IVB 2.5 mg was
administered to the right eye. Subretinal fluid was decreasedright eye (arrows) with subretinal fluid accumulation (star) and lipid exudate at
ter 2.5 mg intravitreal bevacizumab injection; (C) 3 months after photodynamic
ession (arrows). However, massive exudation with bullous retinal detachment
evacizumab and triamcinolone acetonide; and (D) gliotic tumors (arrows) with
Fig. 2. Optical coherence tomography of the right eye macula showed (A)
marked cystoid macular edema and subretinal fluid accumulation at presen-
tation; and (B) significant decrease in the exudation at 1 week after intravitreal
bevacizumab injection.
Fig. 3. Fluorescein angiography of the peripheral retinal capillary hemangioma
(RCH) at temporal retina of the right eye showed (A) early hyperfluorescence;
and (B) marked late phase leakage.
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at 1 week after injection (Figs. 1B and 2B), and BCVA
improved to 5/60. One month later, a session of verteporfin
PDTaccording to the standard protocol for age-related macular
degeneration, combined with IVB 2.5 mg, was performed to
the right eye. PDTwas performed using 6 mg/m2 body surface
area of intravenous verteporfin infused over 10 minutes. Fifteen
minutes after the start of infusion, a laser at wavelength 689 nm
was delivered at 50 J/cm2, with an intensity of 600 mW/cm2
over 83 seconds, using spot sizes of 5000 mm, 5000 mm, and
2000 mm directly to the three tumors, respectively.
Bullous exudative RD developed during the second day,
and BCVA dropped to 3/60. Oral prednisolone 1 mg/kg/day
and two further IVB, one of which was combined with
intravitreal triamcinolone acetonide injection (IVTA) 2 mg,
were performed at 1 month intervals for persistent exudative
RD. Three months after PDT, the tumors had regressed
significantly, but exudative RD persisted (Fig. 1C). External
drainage with scleral buckling, IVB, and IVTA were thus
performed. The retina was attached after surgical intervention
(Fig. 1D), and BCVA improved to 6/60.
Genotyping of the VHL gene of the patient found a C/ T
transition at nucleotide position 694, which resulted in a
nonsense mutation of Arg161stop in exon 3 (Fig. 5A). How-
ever, her parents and three brothers were devoid of this
mutation or any other mutations in the VHL gene (Fig. 5B).
3. Discussion
VHL disease is a multisystem disorder which may be
associated with RCH, central nervous system hemangioma,and other visceral tumors, such as pheochromocytoma and
renal cell carcinoma.1,4 The disease is diagnosed with a
positive family history of VHL disease with one associated
tumor. In the absence of a definite family history, at least two
RCHs or central nervous system hemangiomas, or one hem-
angioma plus one visceral tumor, establish the diagnosis.4 It is
an autosomal dominant disorder caused by mutation in the
VHL tumor suppressor gene located on chromosome 3p25e26.
About 20% of patients with VHL disease have a de novo
mutation of the gene.5 The current patient is a sporadic case of
VHL disease, and is confirmed by the de novo mutation of
codon 161 in VHL gene. Codon 161 mutation is one of the
most common germline mutation sites found in western and
Japanese VHL families,6 and has been reported in Chinese as
well.7 A previous study showed no association between the
mutation point of VHL gene and the severity of RCH,8 but the
visual prognosis of RCH may be worse in patients with
definite VHL disease than in those without VHL disease.9
The prevalence of RCH in patients with VHL disease
ranged from 49% to 85%, and one third of them harbor
multiple RCHs.1 Histopathologically, the RCH is composed of
abnormal capillary-like fenestrated channels surrounded by
vacuolated foamy tumor cells. The capillaries become
incompetent gradually, causing progressive exudation which
may result in macular exudation or exudative RD and thus
Fig. 4. (A) One of the four small retinal capillary hemangiomas in the left eye;
(B) fluorescein angiography showed dye leakage from the tumor; and (C) the
tumors regressed to tiny gliotic nodules after focal laser photocoagulation.
Fig. 5. (A) Genotyping of the VHL gene of the patient’s DNA showed a
transition mutation of C / T at nucleotide 694 (arrow), resulting in a
nonsense mutation of Arg161stop in codon 161; and (B) genotyping of the
patient’s family member showed no mutation in the VHL gene.
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stages can be found in a single patient as in our patient. In the
left eye, the four RCHs were small and were not complicated
with subretinal fluid, whereas the three RCHs in the right eye
were large and complicated with massive exudation. The small
RCHs in the left eye were treated successfully with laser
photocoagulation without any complication. Laser photo-
coagulation is effective in treating RCH smaller than 1.5 mm
with peripheral location and clear media.2
In recent years, PDT has been used in treating large
peripheral RCH with satisfactory results. Extensive literaturereview found 15 cases of peripheral RCH treated with PDT,
including five cases of VHL disease, and most tumors regressed
eventually with decreased exudation.3,10e18 Among the reports,
acuteworsening of cystoidmacula edema has been reported in a
case of peripheral RCH treated with PDT, and resolved at 3
weeks after IVTA.12 Transient increase in subretinal fluid and
subretinal hemorrhage was reported in another three cases of
peripheral RCH treated by PDT, and all resolved spontaneously
within several weeks without intervention.11,17,18 On the
contrary, our case experienced persistent massive exudation
after PDT, despite aggressive treatments with oral prednisolone,
IVB, and IVTA. This is the first reported case of multiple
peripheral RCHs treated by PDT and IVB, in which the tumors
regressed satisfactorily, however, with persistent exudative RD
that required surgical intervention.
Acute posttreatment exudation after PDT has been widely
discussed. Although PDT can bring along significant vascular
closure, vascular hyperpermeability and extravasation happen
in the acute posttreatment stage.19 PDT can also result in acute
closure of the physiological choriocapillaris, causing choroidal
ischemia and exacerbating the posttreatment exudation.20 The
massive subretinal exudation in this case, may be due to the
summation reaction of three large tumors to PDT, instead of
one tumor, as in other reports. Solitary RCH treated with PDT
did not show extensive exudation, even with extended laser
exposure time (166 seconds) or multiple laser spots covering
the tumor and the feeding and draining vessels.10,16 We
therefore suggest that fractionated PDT may be used in cases
with multiple RCHs in which one tumor is treated at a time to
reduce the posttreatment reaction. Furthermore, IVTA may be
used in combination with PDT to reduce the tumor reaction.
Although bevacizumab has the effect of decreasing exudation
by improving the barrier function, as an antivascular
endothelial growth factor, however, the anti-inflammatory
effect may be inferior to that of corticosteroids.
In conclusion, we have reported a rare case of VHL disease
with multiple peripheral RCHs treated by PDT combined with
IVB, which showed significant tumor regression but persistent
exudative RD that required surgical intervention. The massive
56 F.-Y. Tsai et al. / Journal of the Chinese Medical Association 77 (2014) 52e56exudation in this case may be due to the summation reaction of
three large RCHs to PDT. Further studies are warranted to
establish the optimal treatment for multiple RCHs.
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